CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) Rose 18.80% to 97.200 HKD
Newtimespace News, as of 14:16 on May 21, CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) was quoted at HKD 97.200, up 18.80%. The ETF opened at HKD 93.620, with a high of HKD 98.880 and a low of HKD 92.700. The latest Net Asset Value (NAV) per unit is HKD 79.485, with a premium rate of 2.94%. The asset size is approximately HKD 48.523 billion.
CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) is a leveraged and inverse product issued by CSOP Asset Management Limited. It aims to provide, before fees and expenses, investment returns that correspond to twice (2x) the daily performance of the ordinary shares of SK hynix Inc. of South Korea, primarily through the use of financial derivative instruments such as swap contracts. This product features a daily reset mechanism and is a high-risk investment vehicle with significant price volatility. It is typically suitable for experienced and aggressive investors with a clear view on short-term market trends for short-term trading.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CHI MER LAND (00978.HK): JV bid of HKD 1.03 billion for Hung Shui Kiu land accepted, constituting discloseable transaction under alternative size test
- TST PROPERTIES & SINO LAND (00247.HK/00083.HK): Consortium bid of HKD 1.03 billion for Hung Shui Kiu land accepted, JVs established for acquisition and development
- BANK OF CHINA (03988.HK): Completes issuance of RMB 20 billion write-down perpetual capital bonds at coupon rate of 1.86%
- CF PHARMTECH (02652.HK): ICF001 expands indications after implied approval from NMPA, covering four indications including pulmonary fibrosis
- TAI SANG LAND(00089.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 48.32 million, turned profitable from a loss YoY